26 May 2013
Keywords: jerini, merck, kgaa, sign, cancer, deal, germany
Article | 02 February 2004
Germany's Jerini AG and Merck KGaA have entered into a collaboration to develop small-molecule inhibitors against an undisclosed target for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 February 2004
24 May 2013
© 2013 thepharmaletter.com